Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.

The present study sought to investigate the correlation between adipose cytokines (visfatin, leptin and adiponectin) and markers of multiple myeloma bone disease, and to determine the effects and mechanism of action of adiponectin on the differentiation and maturation of osteoclasts in multiple myeloma (MM). The levels of visfatin, leptin and adiponectin were measured. Their association with the indices of myeloma tumor load and bone disease were analyzed. Reverse transcription‑quantitative PCR was used to detect the expression of receptor activator of nuclear factor‑κB ligand (RANKL), osteoclast associated Ig‑like receptor (OSCAR), tartrate‑resistant acid phosphatase (TRAP) and Cathepsin K genes. Flow cytometry was used to detect the expression of adiponectin receptor 1 (AdipoR1) and the phosphorylation of the mechanistic target of rapamycin kinase (mTOR) pathway‑associated proteins mTOR and eukaryotic translation initiation factor 4E‑binding protein (4EBP1). There were no significant correlations among leptin, visfatin and the indexes of myeloma tumor load and bone disease. Serum adiponectin levels were significantly lower in patients with newly diagnosed multiple myeloma compared with healthy volunteers (12.37±3.13 vs. 13.80±0.95; P<0.05). The number of mature osteoclasts in the adiponectin group was lower compared with in the control group. Adiponectin also inhibited the mRNA expression of the osteoclast‑associated factors RANKL, OSCAR, TRAP and Cathepsin K. Comparison between the non‑adiponectin group and the adiponectin group revealed that adiponectin increased the expression of AdipoR1 on the surface of osteoclast precursor cells (26.21±4.27% vs. 29.86±6.23%; P<0.05) and reduced the expression of phosphorylated (p‑)mTOR (7.89±1.00% vs. 5.91±1.26%; P<0.05) and p‑4EBP1 (26.78±5.00% vs. 22.49±4.24%; P<0.05). The p‑mTOR and p‑4EBP1 levels in the adiponectin + MHY1485 (an mTOR signaling pathway‑specific agonist) group were significantly higher compared with those in the adiponectin group. It was revealed that adiponectin may inhibit osteoclast differentiation and maturation via the mTOR pathway. In conclusion, adiponectin inhibits the differentiation and maturation of osteoclasts by increasing the expression of AdipoR1 and reducing the phosphorylation levels of mTOR and 4EBP1 in patients with MM.